skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Base de dados/Biblioteca: EBSCOhost Academic Search Premier remover Nome da Publicação: Value In Health remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
CO172 Immunosuppression Therapy in Retinal Pigmented Epithelial Cell Transplantation: A Targeted Literature Review
CO172 Immunosuppression Therapy in Retinal Pigmented Epithelial Cell Transplantation: A Targeted Literature Review
Material Type:
Artigo 		Adicionar ao Meu Espaço

CO172 Immunosuppression Therapy in Retinal Pigmented Epithelial Cell Transplantation: A Targeted Literature Review

Su, J. ; Kistler, K. ; Schwartz, J.

Value in health, 2023-06, Vol.26 (6), p.S47-S47 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More
Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact of Body Mass Index on the Incidence of Cardiometabolic Risk Factors in Ambulatory Care Settings over 5 Years or More

Said, Qayyim, PhD ; Marx, Carrie McAdam, MS, RPh ; Schwartz, J. Sanford, MD ; Ben-Joseph, Rami, PhD ; Brixner, Diana I., PhD, RPh

Value in health, 2010-03, Vol.13 (2), p.265-272 [Periódico revisado por pares]

Malden, USA: Elsevier Inc

Texto completo disponível

Citações Citado por
3
PRO70 PATIENT-REPORTED OUTCOMES (PRO) LANDSCAPE ASSESSMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD): A TARGETED LITERATURE REVIEW
PRO70 PATIENT-REPORTED OUTCOMES (PRO) LANDSCAPE ASSESSMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD): A TARGETED LITERATURE REVIEW
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRO70 PATIENT-REPORTED OUTCOMES (PRO) LANDSCAPE ASSESSMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD): A TARGETED LITERATURE REVIEW

Schultz, N.M. ; Braunack-Mayer, L. ; Schwartz, J. ; Gaspar, L.

Value in health, 2020-05, Vol.23, p.S340-S341 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
PDB80 WHICH OUTCOME & QUALITY MEASURES DO LEADING KOLS WHO TREAT NONALCOHOLIC STEATOHEPATITIS (NASH) RECOMMEND FOR VALUE-BASED CONTRACTING ACROSS MULTIPLE STAKEHOLDERS?
PDB80 WHICH OUTCOME & QUALITY MEASURES DO LEADING KOLS WHO TREAT NONALCOHOLIC STEATOHEPATITIS (NASH) RECOMMEND FOR VALUE-BASED CONTRACTING ACROSS MULTIPLE STAKEHOLDERS?
Material Type:
Artigo 		Adicionar ao Meu Espaço

PDB80 WHICH OUTCOME & QUALITY MEASURES DO LEADING KOLS WHO TREAT NONALCOHOLIC STEATOHEPATITIS (NASH) RECOMMEND FOR VALUE-BASED CONTRACTING ACROSS MULTIPLE STAKEHOLDERS?

Blackham, J. ; Strapp, J. ; Mitchell, E. ; Schwartz, J.

Value in health, 2019-05, Vol.22, p.S154-S154 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
PCV15 Cost-Effectiveness of Screening for and Treating Masked Hypertension with out-of-Office Blood Pressure Monitoring
PCV15 Cost-Effectiveness of Screening for and Treating Masked Hypertension with out-of-Office Blood Pressure Monitoring
Material Type:
Artigo 		Adicionar ao Meu Espaço

PCV15 Cost-Effectiveness of Screening for and Treating Masked Hypertension with out-of-Office Blood Pressure Monitoring

Green, M. ; Shimbo, D. ; Schwartz, J. ; Bress, A.P. ; King, J. ; Muntner, P. ; Sheppard, J. ; McManus, R. ; Moran, A.E. ; Bellows, B.K.

Value in health, 2021-06, Vol.24, p.S69-S69 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
PHP94 - Evaluating The Cost-Utility Of Immunosuppressive Regimens In Liver Transplant Recipients In Canada
PHP94 - Evaluating The Cost-Utility Of Immunosuppressive Regimens In Liver Transplant Recipients In Canada
Material Type:
Artigo 		Adicionar ao Meu Espaço

PHP94 - Evaluating The Cost-Utility Of Immunosuppressive Regimens In Liver Transplant Recipients In Canada

Pollock, RF ; Schwartz, J ; Howell, J ; Spalding, J

Value in health, 2017-10, Vol.20 (9), p.A668-A668 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
7
Evaluating The Cost-Utility Of Immunosuppressive Regimens In Liver Transplant Recipients In Canada
Evaluating The Cost-Utility Of Immunosuppressive Regimens In Liver Transplant Recipients In Canada
Material Type:
Artigo 		Adicionar ao Meu Espaço

Evaluating The Cost-Utility Of Immunosuppressive Regimens In Liver Transplant Recipients In Canada

Pollock, RF ; Schwartz, J ; Howell, J ; Spalding, J

Value in health, 2017-10, Vol.20 (9), p.A668 [Periódico revisado por pares]

Lawrenceville: Elsevier Science Ltd

Texto completo disponível

Citações Citado por
8
How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?
How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?
Material Type:
Artigo 		Adicionar ao Meu Espaço

How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?

Paglia, R ; Del Carlo, A ; Schwartz, J ; Carter, EA

Value in health, 2017-10, Vol.20 (9), p.A409 [Periódico revisado por pares]

Lawrenceville: Elsevier Science Ltd

Texto completo disponível

Citações Citado por
9
SY3 - How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?
SY3 - How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?
Material Type:
Artigo 		Adicionar ao Meu Espaço

SY3 - How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents as Therapy Areas Become Crowded with Drugs with Similar Mechanisms of Action?

Paglia, R ; Del Carlo, A ; Schwartz, J ; Carter, EA

Value in health, 2017-10, Vol.20 (9), p.A409-A409 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
10
PCN204 - What Is The Future Of Using Outcomes-Based Contracts Between Payers And Pharmaceutical Manufacturers To Gain Market Access For Advanced Oncologic And Biologic Agents?
PCN204 - What Is The Future Of Using Outcomes-Based Contracts Between Payers And Pharmaceutical Manufacturers To Gain Market Access For Advanced Oncologic And Biologic Agents?
Material Type:
Artigo 		Adicionar ao Meu Espaço

PCN204 - What Is The Future Of Using Outcomes-Based Contracts Between Payers And Pharmaceutical Manufacturers To Gain Market Access For Advanced Oncologic And Biologic Agents?

Paglia, R ; Blackham, J ; Del Carlo, A ; Schwartz, J ; Carter, EA ; Foy, C ; Dyson, S ; Areteou, T

Value in health, 2018-05, Vol.21, p.S44-S44 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.